Hepatitis B antiviral agents

Inventors

Qiu, Yao-Ling • Gao, Xuri • Kass, Jorden • Cao, Hui • Li, Wei • Peng, Xiaowen • Suh, Byung-Chul • Or, Yat Sun

Assignees

Enanta Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12011425-B2

Patent

Publication Date

2024-06-18

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Core Innovation

The invention relates to a pharmaceutical composition comprising a compound represented by a formula wherein R is hydrogen or fluorine, together with a pharmaceutically acceptable carrier or excipient. The disclosed embodiments include formula variants and the specific chemical structure shown in the figures or images, with fluorinated aromatic ring systems, chlorine substitution, and sulfonyl or sulfone features.

The structural scope also includes heteroaryl, amide/anilide, bicyclic, and stereochemical variations, together with salts, prodrugs, deuterated analogs, and isotopically labeled compounds where described. The embodiments further include stable or isomeric forms, salt and ester forms, and variants with stereochemical or tautomeric forms.

The disclosure further indicates therapeutic use in hepatitis B virus infection, including treatment by administering a therapeutically effective amount of the pharmaceutical composition to a subject. Additional description connects some embodiments to HBV capsid targeting, inhibition of HBV-encoded proteins, disruption of the HBV life cycle, and effects on HBV replication.

Claims Coverage

The provided claim coverage centers on one pharmaceutical composition claim defined by a compound represented by a formula in which R is hydrogen or fluorine, together with a pharmaceutically acceptable carrier or excipient. The independent claim family contains one central inventive composition feature, with dependent refinements narrowing the included compound to the specific structure shown in the figures or images and narrowing use to treating hepatitis B virus infection.

Pharmaceutical composition with formula-defined compound and carrier or excipient

A pharmaceutical composition comprising a compound represented by the formula wherein R is hydrogen or fluorine, together with a pharmaceutically acceptable carrier or excipient.

Specific chemical structure shown in the figures or images

The pharmaceutical composition further defines the included compound as the specific chemical structure shown in the figures or images.

Treatment of hepatitis B virus infection

The pharmaceutical composition is used for treating a hepatitis B virus infection by administering a therapeutically effective amount to a subject.

Overall, the claim coverage is directed to a pharmaceutical composition defined by a formula compound with R being hydrogen or fluorine, narrowed to the specific depicted structures, and further limited to treatment of hepatitis B virus infection by administering a therapeutically effective amount.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treating a hepatitis B virus infection by administering a therapeutically effective amount of the pharmaceutical composition to a subject.

HBV treatment/prevention, including addressing HBV infection and HBV replication.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.